The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition
Open accessAbstract
BACKGROUNDWhether a broadly neutralizing antibody (bnAb) can be used to prevent human immunodeficiency virus type 1 (HIV-1) acquisition is unclear. METHODSWe enrolled at-risk cisgender men and transgender persons in the Americas and Europe in the HVTN 704/HPTN 085 trial and at-risk women in sub-Saharan Africa in the HVTN 703/HPTN 081 trial.Participants were randomly assigned to receive, every 8 weeks, infusions of a bnAb (VRC01) at a dose of either 10 or 30 mg per kilogram (low-dose group and high-dose group, respectively) or placebo, for 10 infusions in total.HIV-1 testing was performed every 4 weeks.The VRC01 80% inhibitory concentration (IC 80 ) of acquired isolates was measured with the TZM-bl assay. RESULTSAdverse events were similar in number and severity among the treatment groups within each trial.Among the 2699 participants in HVTN 704/HPTN 085, HIV-1 infection occurred in 32 in the low-dose group, 28 in the high-dose group, and 38 in the placebo group.Among the 1924 participants in HVTN 703/HPTN 081, infection occurred in 28 in the low-dose group, 19 in the high-dose group, and 29 in the placebo group.The incidence of HIV-1 infection per 100 person-years in HVTN 704/ HPTN 085 was 2.35 in the pooled VRC01 groups and 2.98 in the placebo group (estimated prevention efficacy, 26.6%; 95% confidence interval [CI], -11.7 to 51.8; P = 0.15), and the incidence per 100 person-years in HVTN 703/HPTN 081 was 2.49 in the pooled VRC01 groups and 3.10 in the placebo group (estimated prevention efficacy, 8.8%; 95% CI, -45.1 to 42.6; P = 0.70).In prespecified analyses pooling data across the trials, the incidence of infection with VRC01-sensitive isolates (IC 80 <1 μg per milliliter) per 100 person-years was 0.20 among VRC01 recipients and 0.86 among placebo recipients (estimated prevention efficacy, 75.4%; 95% CI, 45.5 to 88.9).The prevention efficacy against sensitive isolates was similar for each VRC01 dose and trial; VRC01 did not prevent acquisition of other HIV-1 isolates. CONCLUSIONSVRC01 did not prevent overall HIV-1 acquisition more effectively than placebo, but analyses of VRC01-sensitive HIV-1 isolates provided proof-of-concept that bnAb prophylaxis can be effective.(Supported by the National Institute of Allergy and Infectious Diseases; HVTN 704/HPTN 085 and HVTN 703/HPTN 081 ClinicalTrials .govnumbers, NCT02716675 and NCT02568215.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Notably, the broadly neutralizing mAbs, VRC01, have recently gained attention thanks to their ability to neutralize 98% of HIV strains167 and prevent transmission of antibody-sensitive strains with 75.4% efficacy168.”
From mRNA vaccines for infectious diseases: principles, delivery and clinical translation (2021) · cites this paper as [168]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1
Wu, X., Yang, Z., Li, Y., Högerkorp, C., Schief, W. R., Seaman, M. S., Zhou, T., Schmidt, S. D., Wu, L., Xu, L., et al. (2010) · Science · doi:10.1126/science.1187659 · Cited by 1,724
Self-citationBroad neutralization coverage of HIV by multiple highly potent antibodies
Walker, L. M., Huber, M., Doores, K. J., Falkowska, E., Pejchal, R., Julien, J.-P., Wang, S.-K., Ramos, A., Chan-Hui, P.-Y., Moyle, M., et al. (2011) · Nature · doi:10.1038/nature10373 · Cited by 1,480
Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding
Scheid, J. F., Mouquet, H., Ueberheide, B. M., Diskin, R., Klein, F., Oliveira, T. Y., Pietzsch, J., Fenyö, D., Abadir, A., Velinzon, K., et al. (2011) · Science · doi:10.1126/science.1207227 · Cited by 1,161
Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01
Zhou, T., Georgiev, I. S., Wu, X., Yang, Z., Dai, K., Finzi, A., Kwon, Y. D., Scheid, J. F., Shi, W., Xu, L., et al. (2010) · Science · doi:10.1126/science.1192819 · Cited by 1,123
Self-citationSeaman, M. S., Janes, H., Hawkins, N. R., Grandpre, L. E., Devoy, C., Giri, A., Coffey, R., Harris, L. J., Wood, B., Daniels, M., et al. (2009) · Journal of Virology · doi:10.1128/jvi.02108-09 · Cited by 626
Self-citationEfficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine
Hammer, S. M., Sobieszczyk, M. E., Janes, H., Karuna, S., Mulligan, M. J., Grove, D., Koblin, B. A., Buchbinder, S., Keefer, M. C., Tomaras, G. D., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1310566 · Cited by 618
Self-citationMeasuring HIV Neutralization in a Luciferase Reporter Gene Assay
Montefiori, D. C. (2009) · Methods in molecular biology · doi:10.1007/978-1-59745-170-3_26 · Cited by 585
Self-citationCombination therapy with anti-HIV-1 antibodies maintains viral suppression
Mendoza, P., Gruell, H., Nogueira, L., Pai, J. A., Butler, A. L., Millard, K. G., Lehmann, C., Suárez, I., Oliveira, T. Y., Lorenzi, J. C. C., et al. (2018) · Nature · doi:10.1038/s41586-018-0531-2 · Cited by 560
Sarzotti‐Kelsoe, M., Bailer, R. T., Turk, E., Lin, C.-L., Bilska, M., Greene, K., Gao, H., Todd, C. A., Ozaki, D. A., Seaman, M. S., et al. (2013) · Journal of Immunological Methods · doi:10.1016/j.jim.2013.11.022 · Cited by 535
Self-citationEffect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption
Bar, K. J., Sneller, M. C., Harrison, L. J., Justement, J. S., Overton, E. T., Petrone, M. E., Salantes, D. B., Seamon, C. A., Scheinfeld, B., Kwan, R. W., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1608243 · Cited by 466
Self-citation
Flagged first, then by citations
Research works printed but not linked: 2
- 10.1128/JVI.00991-17 · DOI
- Mahomed S, Garrett N, Baxter C, Abdool Karim Q, Abdool Karim SS. Clinical trials of broadly neutralizing monoclonal antibodies for HIV prevention: a review. J Infect Dis 2020 June 30 (Epub ahead of print).32604408
Cited by
Sorted by citations
Items 201–300 of 534
Kwon, Y. D., Pegu, A., Yang, E. S., Zhang, B., Bender, M. F., Asokan, M., Liu, Q., McKee, K., Lin, B. C., Liu, T. W. B., et al. (2023) · mAbs · doi:10.1080/19420862.2023.2223350 · Cited by 9
Self-citationSuphaphiphat, K., Desjardins, D., Lorin, V., Dimant, N., Bouchemal, K., Bossevot, L., Galpin-Lebreau, M., Dereuddre‐Bosquet, N., Mouquet, H., Grand, R. L., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41966-4 · Cited by 9
Zhu, Y., Gao, F., Glidden, D. V., Donnell, D. J., & Janes, H. (2023) · Clinical Trials · doi:10.1177/17407745231203327 · Cited by 9
Self-citationHuang, Y., Zhang, L., Karuna, S., Andrew, P., Juraska, M., Weiner, J. A., Angier, H. E., Morgan, E., Azzam, Y., Swann, E. M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-43399-5 · Cited by 9
Self-citationKoornneef, A., Vanshylla, K., Hardenberg, G., Rutten, L., Strokappe, N. M., Tolboom, J. T. B. M., Vreugdenhil, J., Boer, K. F.-D., Perkasa, A., Blokland, S., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47492-1 · Cited by 9
Alba, C., Malhotra, S., Horsfall, S., Barnhart, M. E., Bekker, A., Chapman, K., Cunningham, C. K., Fast, P., Fouda, G. G., Freedberg, K. A., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0318940 · Cited by 9
Diverse antiviral IgG effector activities are predicted by unique biophysical antibody features
Cheng, H. D., Dowell, K. G., Bailey‐Kellogg, C., Goods, B. A., Love, J. C., Ferrari, G., Alter, G., Gach, J. S., Forthal, D. N., Lewis, G. K., et al. (2021) · Retrovirology · doi:10.1186/s12977-021-00579-9 · Cited by 9
Self-citationEstimation of vaccine efficacy for variants that emerge after the placebo group is vaccinated
Follmann, D. A., Fay, M. P., Magaret, C. A., & Gilbert, P. (2022) · Statistics in Medicine · doi:10.1002/sim.9405 · Cited by 9
Self-citationPreventive HIV Vaccines-Leveraging on Lessons from the Past to Pave the Way Forward
Sobia, P., & Archary, D. (2021) · Vaccines · doi:10.3390/vaccines9091001 · Cited by 10
Goldberg, B. S., Kaku, C. I., Dufloo, J., Bruel, T., Schwartz, O., Spencer, D. A., Hessell, A. J., & Ackerman, M. E. (2021) · mBio · doi:10.1128/mbio.01743-21 · Cited by 9
Thomas, A. S., Coote, C., Moreau, Y., Isaac, J. E., Ewing, A. C., Kourtis, A. P., & Sagar, M. (2022) · JCI Insight · doi:10.1172/jci.insight.159435 · Cited by 9
Becerra, J. C., Hitchcock, L., Vu, K., & Gach, J. S. (2024) · Microbial Cell · doi:10.15698/mic2024.07.826 · Cited by 8
Priming antibody responses to the fusion peptide in rhesus macaques
Cottrell, C. A., Pratap, P. P., Cirelli, K. M., Carnathan, D. G., Enemuo, C. A., Antanasijevic, A., Ozorowski, G., Sewall, L. M., Gao, H., Allen, J. D., et al. (2024) · npj Vaccines · doi:10.1038/s41541-024-00918-9 · Cited by 8
Self-citationPahus, M. H., Zheng, Y., Olefsky, M., Gunst, J. D., Tebas, P., Taiwo, B., Søgaard, O. S., Peluso, M. J., Lie, Y., Reeves, J. D., et al. (2024) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiae486 · Cited by 8
Enhancing broadly neutralising antibody suppression of HIV by immune modulation and vaccination
Nel, C., & Frater, J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1478703 · Cited by 9
Elliott, T., Bradshaw, D., & Fidler, S. J. (2025) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000919 · Cited by 8
Moodie, Z., Li, S. S., Giorgi, E. E., Williams, L. D., Dintwe, O., Carpp, L. N., Chen, S., Seaton, K. E., Sawant, S. S., Zhang, L., et al. (2025) · Emerging Microbes & Infections · doi:10.1080/22221751.2025.2485317 · Cited by 8
Self-citationSutar, J., Jayal, P., Mullick, R., Chaudhary, S., Kamble, P., Bhowmick, S., Kaginkar, S., Padwal, V., Devadiga, P., Neman, N., et al. (2025) · Journal of Virology · doi:10.1128/jvi.00008-25 · Cited by 8
A broad antibody with enhanced HIV-1 neutralization via bispecific antibody-mediated prepositioning
Kim, S., Radford, C. E., Xu, D., Zhong, J., Do, J., Pham, D. M., Travisano, K. A., Interrante, M. V. F., Bruun, T. U. J., Rezek, V. K., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-60035-6 · Cited by 8
Morris, D. J., Gorman, J., Zhou, T., Lora, J., Connell, A. J., Li, H., Liu, W., Roark, R. S., Campion, M. S., Carey, J. W., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115848 · Cited by 8
van Schooten, J., Schorcht, A., Farokhi, E., Umotoy, J. C., Gao, H., van den Kerkhof, T. L. G. M., Dorning, J., Meesters, T. G. R., van der Woude, P., Burger, J. A., et al. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1010945 · Cited by 8
Self-citationDelivery platforms for broadly neutralizing antibodies
Joshi, L. R., Gálvez, N. M. S., Ghosh, S., Weiner, D. B., & Balazs, A. B. (2023) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000803 · Cited by 10
Development of screening assays for use of broadly neutralizing antibodies in people with HIV
Lynch, R. M., & Bar, K. J. (2023) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000798 · Cited by 8
‘Immunization during ART and ATI for HIV-1 vaccine discovery/development’
Stamatatos, L. (2023) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000817 · Cited by 8
3D human tissue models and microphysiological systems for HIV and related comorbidities
Yin, D. E., Palin, A., Lombo, T., Mahon, R. N., Poon, B., Wu, D.-Y., Atala, A., Brooks, K. M., Chen, S., Coyne, C. B., et al. (2023) · Trends in biotechnology · doi:10.1016/j.tibtech.2023.10.008 · Cited by 9
Wang, S., Chan, K.-W., Wei, D., Ma, X., Liu, S., Hu, G., Park, S., Pan, R., Gu, Y., Nazzari, A. F., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-48514-8 · Cited by 8
Self-citationViolari, A., Otwombe, K. N., Hahn, W. O., Chen, S., Josipovic, D., Baba, V., Angelidou, A., Smolen, K. K., Levy, O., Mkhize, N. N., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci186927 · Cited by 8
Self-citationvan Dorsten, R. T., Wagh, K., Moore, P. L., & Morris, L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.734110 · Cited by 8
Self-citationDevelopment of Neutralization Breadth against Diverse HIV‐1 by Increasing Ab–Ag Interface on V2
Gao, N., Gai, Y., Meng, L., Wang, C., Wang, W., Li, X., Gu, T., Louder, M. K., Doria‐Rose, N. A., Wiehe, K. J., et al. (2022) · Advanced Science · doi:10.1002/advs.202200063 · Cited by 8
Self-citationZhao, F., Berndsen, Z. T., Pedreño-López, N., Burns, A., Allen, J. D., Barman, S., Lee, W.-H., Chakraborty, S., Gnanakaran, S., Sewall, L. M., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32783-2 · Cited by 8
Personalizing prevention: Advances in pharmacotherapy for HIV prevention
Brizzi, M. B., Sherman, E. M., Green, S. B., Nowicki, D. N., Drwiega, E. N., Nicol, M. R., Chastain, D. B., Sahloff, E. G., Truong, W. R., Cluck, D. B., et al. (2023) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2796 · Cited by 8
Dankwa, S., Kosman, C., Dennis, M. L., Giorgi, E. E., Vuong, K., Pahountis, I., Garza, A., Binuya, C. R., McCarthy, J., Mayer, B. T., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0312411 · Cited by 7
Cale, E. M., Shen, C., Olia, A. S., Radakovich, N. A., Rawi, R., Yang, Y., Ambrozak, D. R., Bennici, A. K., Chuang, G., Crooks, E. D., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.115010 · Cited by 7
Self-citationCohen, P., Lambson, B. E., Mkhize, N. N., Moodley, C., Yssel, A., Moyo-Gwete, T., York, T., Gwashu-Nyangiwe, A., Ndabambi, N., Thebus, R., et al. (2025) · Journal of Virology · doi:10.1128/jvi.01730-24 · Cited by 7
Self-citationEstrogen Modulation of B Cell Immunity: Implications for HIV Control and Therapeutic Strategies
Kasibante, J., Brown, T. T., Lake, J. E., & Abdel‐Mohsen, M. (2025) · Comprehensive physiology · doi:10.1002/cph4.70050 · Cited by 7
Mullins, J. I., Deng, W., Giorgi, E. E., Magaret, C. A., Rolland, M., Tanmoy Bhattacharya, A., Westfall, D. H., Yssel, A., Bumgarner, R. E., Murrell, B., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-73496-0 · Cited by 7
Self-citationAssessment of an LSDV-Vectored Vaccine for Heterologous Prime-Boost Immunizations against HIV
Chapman, R. E., van Diepen, M. T., Douglass, N., Galant, S., Jaffer, M. A., Margolin, E., Ximba, P., Hermanus, T., Moore, P. L., & Williamson, A. (2021) · Vaccines · doi:10.3390/vaccines9111281 · Cited by 7
Zhou, S., Long, N., & Swanstrom, R. I. (2023) · Frontiers in Virology · doi:10.3389/fviro.2023.1291996 · Cited by 7
Wu, C., Raheem, I. T., Nahas, D. D., Citron, M. P., Kim, P. S., Montefiori, D. C., Ottinger, E. A., Hepler, R. W., Hrin, R. C., Patel, S. B., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2317230121 · Cited by 7
Self-citationLemos, M. P., Astronomo, R. D., Huang, Y., Narpala, S., Prabhakaran, M. S., Mann, P., Paez, C. A., Lu, Y., Mize, G. J., Glantz, H., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54580-9 · Cited by 7
Self-citationCaskey, M. F., & Kuritzkes, D. R. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac751 · Cited by 8
Features of functional and dysfunctional CD8+ T cells to guide HIV vaccine development
Bhattacharyya, S., Crain, C. R., Goldberg, B. S., & Gaiha, G. D. (2023) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000812 · Cited by 7
HIResist: a database of HIV-1 resistance to broadly neutralizing antibodies
Misra, M., Jeffy, J., Liao, C., Pickthorn, S., Wagh, K., & Herschhorn, A. (2024) · Bioinformatics · doi:10.1093/bioinformatics/btae103 · Cited by 7
FcγR Genetic Variation and HIV-1 Vaccine Efficacy: Context And Considerations
Lassaunière, R., & Tiemessen, C. T. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.788203 · Cited by 7
Study design approaches for future active-controlled HIV prevention trials
Donnell, D. J., Kansiime, S., Glidden, D. V., Luedtke, A. R., Gilbert, P. B., Gao, F., & Janes, H. (2023) · Statistical Communications in Infectious Diseases · doi:10.1515/scid-2023-0002 · Cited by 7
Self-citationUnder the Radar: Immune Evasion, Pathogenesis and Control of HIV Infection
Tarrés-Freixas, F., Trinité, B., Carrillo, J., & Blanco, J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262311381 · Cited by 6
A Semiparametric Cox–Aalen Transformation Model with Censored Data
Ning, X., Pan, Y., Sun, Y., & Gilbert, P. B. (2023) · Biometrics · doi:10.1111/biom.13895 · Cited by 6
Self-citationDohadwala, S., Geib, M. T., Politch, J. A., & Anderson, D. J. (2024) · Frontiers in Reproductive Health · doi:10.3389/frph.2023.1337479 · Cited by 7
Nucleic Acid Vaccines Encoding Proteins and Virus-like Particles for HIV Prevention
Tarrés-Freixas, F., Clotet, B., Carrillo, J., & Blanco, J. (2024) · Vaccines · doi:10.3390/vaccines12030298 · Cited by 6
Ultrapotent Broadly Neutralizing Human‐llama Bispecific Antibodies against HIV‐1
Xu, J., Zhou, T., McKee, K., Zhang, B., Liu, C., Nazzari, A. F., Pegu, A., Shen, C., Becker, J. E., Bender, M. F., et al. (2024) · Advanced Science · doi:10.1002/advs.202309268 · Cited by 6
RNA-Based Vaccines and Therapeutics Against Intracellular Pathogens
Kola, N. S., Patel, D., & Thakur, A. (2024) · Methods in molecular biology · doi:10.1007/978-1-0716-3890-3_21 · Cited by 6
Comparison of the immunogenicity of mRNA-encoded and protein HIV-1 Env–ferritin nanoparticle designs
Mu, Z., Whitley, J., Martik, D., Sutherland, L. L., Newman, A., Barr, M., Parks, R., Wiehe, K. J., Cain, D. W., Hodges, K. Z., et al. (2024) · Journal of Virology · doi:10.1128/jvi.00137-24 · Cited by 6
Bick, M., Puig, E., Beauparlant, D., Nedellec, R., Burton, I., Ardaghi, K., Zalunardo, T. R., Bastidas, R. B., Li, X., Guenaga, J., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115331 · Cited by 6
Anticipating HIV viral escape – resistance to active and passive immunization
Williamson, C. E., Lynch, R. M., & Moore, P. L. (2023) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000816 · Cited by 6
Self-citationXu, S., Kelkar, N. S., & Ackerman, M. E. (2024) · iScience · doi:10.1016/j.isci.2024.109086 · Cited by 6
Garber, D. A., Guenthner, P. C., Mitchell, J. M., Ellis, S., Gazumyan, A., Nason, M., Seaman, M. S., McNicholl, J. M., Nussenzweig, M. C., & Heneine, W. (2021) · AIDS · doi:10.1097/qad.0000000000002934 · Cited by 6
Bhiman, J. N., & Moore, P. L. (2022) · Immunological Reviews · doi:10.1111/imr.13086 · Cited by 7
Fitting a vaccine into the HIV prevention landscape
Fauci, A. S., Dieffenbach, C. W., & Dabis, F. (2021) · Journal of the International AIDS Society · doi:10.1002/jia2.25792 · Cited by 6
A General Framework for Inference on Algorithm-Agnostic Variable Importance
Williamson, B. D., Gilbert, P. B., Simon, N., & Carone, M. (2021) · Figshare · doi:10.6084/m9.figshare.16967331 · Cited by 6
Self-citationMaciel, M., Baden, L. R., Briney, B. S., Doria-Rose, N. A., Kiwanuka, K. N., Krebs, S. J., Malaspina, A., Tomaras, G. D., Ward, A., Hedestam, G. B. K., et al. (2025) · npj Vaccines · doi:10.1038/s41541-025-01168-z · Cited by 5
Self-citationHIV Therapy: The Latest Developments in Antiviral Drugs—A Scoping Review
Fanjul, F. J., Gavaldà, M., Campins, A. A., Ferre, A., Martín, L., Peñaranda, M., Ribas, M. Á., Pastor-Ramón, E., Socias, S. P., & Riera, M. (2025) · Biomedicines · doi:10.3390/biomedicines13112629 · Cited by 5
Williamson, C. E., Moodley, C., Magaret, C. A., Giorgi, E. E., Rolland, M., Westfall, D. H., Yssel, A., Deng, W., Rossenkhan, R., Mkhize, N. N., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-70888-0 · Cited by 5
Self-citationRahman, M. A., Bissa, M., Scinto, H. B., Howe, S. E., Sarkis, S., Ma, Z.-M., Gutowska, A., Jiang, X., Luo, C. C., Schifanella, L., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-53359-2 · Cited by 5
Monoclonal Antibodies for Pediatric Viral Disease Prevention and Treatment
Bahadir, Z., Narayan, P., Wolters, R. M., Permar, S. R., Fouda, G. G., Hessell, A. J., & Haigwood, N. L. (2025) · PEDIATRICS · doi:10.1542/peds.2024-068690 · Cited by 6
Seaton, K. E., Paez, C. A., Yu, C., Karuna, S., Gamble, T., Miner, M. D., Heptinstall, J., Zhang, L., Gao, F., Yacovone, M. A., et al. (2025) · The Lancet HIV · doi:10.1016/s2352-3018(25)00012-8 · Cited by 5
Self-citationPolyfunctionality of broadly neutralizing HIV-1 antibodies
Vrignaud, L.-L., Schwartz, O., & Bruel, T. (2023) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000799 · Cited by 5
Data Fusion Using Weakly Aligned Sources
Li, S., Gilbert, P. B., Duan, R., & Luedtke, A. R. (2025) · Journal of the American Statistical Association · doi:10.1080/01621459.2025.2476780 · Cited by 5
Self-citationEmerging drugs for the treatment of HIV/AIDS: a review of 2019/2020 phase II and III trials
Piscaglia, M., Cossu, M. V., Passerini, M., Petri, F., Gerbi, M., Fusetti, C., Capetti, A. F., & Rizzardini, G. (2021) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2021.1946036 · Cited by 5
Madan, B., Reddem, E. R., Wang, P., Casner, R. G., Nair, M. S., Huang, Y., Fahad, A. S., de Souza, M. O., Banach, B. B., Acevedo, S. N. L., et al. (2021) · AIChE Journal · doi:10.1002/aic.17440 · Cited by 6
Self-citationImproved efficiency for cross-arm comparisons via platform designs
Huang, T.-J., Luedtke, A. R., & THE AMP INVESTIGATOR GROUP (2022) · Biostatistics · doi:10.1093/biostatistics/kxac030 · Cited by 5
Lovelace, S. E., Hait, S. H., Yang, E. S., Fox, M. L., Liu, C., Choe, M., Chen, X., McCarthy, E. E., Todd, J.-P. M., Woodward, R. A., et al. (2022) · iScience · doi:10.1016/j.isci.2022.105067 · Cited by 5
Self-citationGarber, D. A., Guenthner, P. C., Zhao, C., Mitchell, J. M., Ellis, S., Jia, H., Manganare, M., Gazumyan, A., Seaman, M. S., Vishwanathan, S. A., et al. (2022) · AIDS · doi:10.1097/qad.0000000000003472 · Cited by 5
Advances in mRNA vaccines for viral diseases
Huang, Y., Zhu, X., Guo, X., Zhou, Y., Liu, D., Mao, J., Xiong, Y., Deng, Y., & Gao, X. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28924 · Cited by 5
Self-citationSherburn, R. T., Tolbert, W. D., Gottumukkala, S., Hederman, A. P., Beaudoin-Bussières, G., Stanfield-Oakley, S., Tuyishime, M., Ferrari, G., Finzi, A., Ackerman, M. E., et al. (2021) · Vaccines · doi:10.3390/vaccines9090975 · Cited by 5
Advancing bnAb combinations for HIV prevention
Gruell, H., & Schommers, P. (2023) · The Lancet HIV · doi:10.1016/s2352-3018(23)00172-8 · Cited by 5
Health Technology Assessment of mRNA Vaccines: Clinical, Economic, and Public Health Implications
Genovese, G., Rizzo, C. E., & Genovese, C. (2025) · Vaccines · doi:10.3390/vaccines13101045 · Cited by 4
King, H. A. D., Brammer, D., Lewitus, É., Fennessey, C. M., Manalang, K., Shrader, H. R., Andrew, S. F., Kuri, P., Lind, M., Pham, P. T., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2404767122 · Cited by 4
Increased immunogen valency improves the maturation of vaccine-elicited HIV-1 VRC01-like antibodies
Agrawal, P., Khechaduri, A., Salladay, K. R., MacCamy, A. J., Ralph, D., Riker, A. O., Stuart, A. B., Siddaramaiah, L. K., Shen, X., Matsen, F. A., IV, et al. (2025) · PLoS Pathogens · doi:10.1371/journal.ppat.1013039 · Cited by 5
Self-citationAccelerating Innovation: Advancing Opportunities in HIV Vaccine Development
DiazGranados, C. A., Onami, T. M., & Anklesaria, P. N. (2025) · Current HIV Research · doi:10.2174/011570162x364991250710044947 · Cited by 4
Priming VRC01-precursor B cells with non-envelope immunogens disfavors boosting with HIV-1 envelope
Wilcox-King, A., Wan, Y.-H., Scharffenberger, S. C., Chhan, C. B., Davis, A. R., Homad, L. J., Seydoux, E., MacPhee, K. J., Siddaramaiah, L. K., Melo, M. B., et al. (2025) · npj Vaccines · doi:10.1038/s41541-025-01235-5 · Cited by 4
Leone, P. A., Ferro, A., Rolle, C.-P., Lupo, S., McGowan, J. P., Klein, M. B., Cahn, P. E., Benson, P. M., Griesel, R., Warwick‐Sanders, M., et al. (2025) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaf450 · Cited by 4
Bayesian estimation of HIV acquisition dates for prevention trials
Rossenkhan, R., Giorgi, E. E., Shao, D., Ludwig, J., Labuschagne, J. P. L., Magaret, C. A., Ndung’u, T., Muema, D., Gounder, K., Dong, K. L., et al. (2025) · mBio · doi:10.1128/mbio.01881-25 · Cited by 4
Self-citationReiss, E. I. M. M., van der Straten, K., Graus, L. T. M., Grobben, M., Vlaming, K. E., van der Veen, A., Liesdek, M. H., Ozorowski, G., Corcoran, M., Gao, H., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-65101-7 · Cited by 4
Self-citationClinical trial simulation of antiviral drugs
Schiffer, J. T., Reeves, D. B., Mayer, B. T., Rodriguez, L. R., Duke, E. R., Haddock, B., de León, U. A.-P., Iwami, S., Owens, K. L., & Esmaeili, S. (2026) · Journal of Virology · doi:10.1128/jvi.01814-24 · Cited by 4
Rapid boosting increases germinal center responses to sequential vaccines
Haupt, S., Cottrell, C. A., Zhou, X., Lee, J. H., Liguori, A., Alavi, N. B., Lu, D., Phelps, N., Goodwin, D., Ben‐Akiva, E., et al. (2026) · Nature Immunology · doi:10.1038/s41590-026-02549-9 · Cited by 4
Williamson, C. E., Curry, L., Mkhize, N. N., Giorgi, E. E., Magaret, C. A., Lambson, B. E., Bhebhe, S., Kaldine, H., Moyo-Gwete, T., Rolland, M., et al. (2026) · Nature Microbiology · doi:10.1038/s41564-026-02467-4 · Cited by 4
Self-citationRujas, E., Leaman, D. P., Insausti, S., Carravilla, P., García‐Porras, M., Largo, E., Morillo, I., Sánchez‐Eugenia, R., Zhang, L., Cui, H., et al. (2021) · iScience · doi:10.1016/j.isci.2021.102987 · Cited by 4
Adjuvants influence the maturation of VRC01-like antibodies during immunization
Knudsen, M. L., Agrawal, P., MacCamy, A. J., Parks, K. R., Gray, M. D., Takushi, B. N., Khechaduri, A., Salladay, K. R., Coler, R. N., LaBranche, C. C., et al. (2022) · iScience · doi:10.1016/j.isci.2022.105473 · Cited by 4
Self-citationWilson, A., Manuzak, J. A., Liang, H. L., Léda, A. R., Klatt, N. R., & Lynch, R. M. (2022) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2022.0123 · Cited by 4
Iterative hypothesis testing in HIV vaccine research: moving towards success
Anklesaria, P. N., & Russell, N. D. (2023) · Journal of the International AIDS Society · doi:10.1002/jia2.26102 · Cited by 4
Williamson, B. D., Magaret, C. A., Karuna, S., Carpp, L. N., Gelderblom, H. C., Huang, Y., Benkeser, D. C., & Gilbert, P. B. (2023) · iScience · doi:10.1016/j.isci.2023.107595 · Cited by 4
Self-citationPolyfunctionality and breadth of HIV-1 antibodies are associated with delayed disease progression
Grobben, M., Bakker, M. E., Schriek, A. I., Levels, L. J. J., Umotoy, J. C., Tejjani, K., van Breemen, M. J., Lin, R. N., de Taeye, S. W., Ozorowski, G., et al. (2024) · PLoS Pathogens · doi:10.1371/journal.ppat.1012739 · Cited by 4
Blair, C. S., Cambou, M. C., & Landovitz, R. J. (2025) · Annual Review of Medicine · doi:10.1146/annurev-med-042823-013707 · Cited by 4
Active‐Controlled Trial Design for HIV Prevention Trials With a Counterfactual Placebo
Gao, F., Janes, H., Buchbinder, S., & Donnell, D. J. (2025) · Statistics in Medicine · doi:10.1002/sim.70022 · Cited by 4
Self-citationGiorgi, E. E., Abrahams, M.-R., Fouda, G. G., John-Stewart, G. C., Goga, A. E., Mullins, J. I., Permar, S. R., Janes, H., & Martin, T. M. (2025) · Current HIV Research · doi:10.2174/011570162x357975250902104402 · Cited by 4
Self-citationEx Vivo Evaluation of Mucosal Responses to Vaccination with ALVAC and AIDSVAX of Non-Human Primates
Herrera, C., Veazey, R. S., Lemke, M. M., Arnold, K. B., Kim, J. H., & Shattock, R. J. (2022) · Vaccines · doi:10.3390/vaccines10020187 · Cited by 4
HLA-II-Associated HIV-1 Adaptation Decreases CD4 + T-Cell Responses in HIV-1 Vaccine Recipients
Files, J. K., Sterrett, S., Henostroza, S., Fucile, C., Maroney, K. J., Fram, T., Mallal, S. A., Kalams, S. A., Carlson, J. M., Rosenberg, A. F., et al. (2022) · Journal of Virology · doi:10.1128/jvi.01191-22 · Cited by 4
Chapman, R. E., van Diepen, M. T., Douglass, N., Hermanus, T., Moore, P. L., & Williamson, A. (2023) · Vaccines · doi:10.3390/vaccines11020376 · Cited by 4
HIV-1 prehairpin intermediate inhibitors show efficacy independent of neutralization tier
Bell, B. N., Bruun, T. U. J., Friedland, N., & Kim, P. S. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2215792120 · Cited by 4
Metadata
- Authors
- Corey, L., Gilbert, P. B., Juraska, M., Montefiori, D. C., Morris, L., Karuna, S. T., Edupuganti, S., Mgodi, N. M., deCamp, A. C., Rudnicki, E., Huang, Y., Gonzales, P., Cabello, R., Orrell, C., Lama, J. R., Laher, F., Lazarus, E. M., Sanchez, J., Frank, I., Hinojosa, J., Sobieszczyk, M. E., Marshall, K. E., Mukwekwerere, P. G., Makhema, J., Baden, L. R., Mullins, J. I., Williamson, C., Hural, J., McElrath, M. J., Bentley, C., Takuva, S., Gomez Lorenzo, M. M., Burns, D. N., Espy, N., Randhawa, A. K., Kochar, N., Piwowar-Manning, E., Donnell, D. J., Sista, N., Andrew, P., Kublin, J. G., Gray, G., Ledgerwood, J. E., Mascola, J. R., & Cohen, M. S.
- Affiliations
- University of the Witwatersrand (ZA)
- National Health Laboratory Service (ZA)
- Emory University (US)
- University of Zimbabwe (ZW)
- From the Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center (L.C., P.B.G., M.J., S.T.K., A.C.C., E.R., Y.H., K.E.M., J. Hural, M.J.M.E., C.B., S.T., N.E., A.K.R., N.K., D.J.D., J.G.K., G.G.), and the Departments of Global Health, Microbiology, and Medicine, University of Washington (J.I.M.), Seattle; the Department of Surgery and Duke Human Vaccine Institute, Duke University Medical Center (D.C.M.), and FHI 360 (N.S., P.A.), Durham, and the Institute for Global Health and Infectious Disease, University of North Carolina, Chapel Hill (M.S.C.) — both in North Carolina; the National Institute for Communicable Diseases of the National Health Laboratory Service (L.M.) and the Antibody Immunity Research Unit, Faculty of Health Sciences (L.M.), and the Perinatal HIV Research Unit, Faculty of Health Sciences (F.L., E.M.L., S.T.), University of the Witwatersrand, Johannesburg, the Desmond Tutu HIV Centre, Department of Medicine and Institute of Infectious Disease and Molecular Medicine ...
- Brigham and Women's Hospital (US)
- University of Cape Town (ZA)
- Family Health International 360 (US)
- South African Medical Research Council (ZA)
- University of North Carolina at Chapel Hill (US)
- ORCID
- Corey, Lawrence
- Gilbert, Peter B.
- Juraska, Michal
- Montefiori, David C.
- Morris, Lynn
- Karuna, Shelly T.
- Edupuganti, Srilatha
- Mgodi, Nyaradzo M.
- deCamp, Allan C.
- Huang, Yunda
- Cabello, Robinson
- Orrell, Catherine
- Lama, Javier R.
- Laher, Fatima
- Lazarus, Erica M.
- Frank, Ian
- Sobieszczyk, Magdalena E.
- Marshall, Kyle E.
- Mukwekwerere, Pamela G.
- Makhema, Joseph
- Baden, Lindsey R.
- Mullins, James I.
- Williamson, Carolyn
- Hural, John
- McElrath, M. Juliana
- Takuva, Simbarashe
- Burns, David N.
- Espy, Nicole
- Randhawa, April K.
- Donnell, Deborah J.
- Andrew, Philip
- Kublin, James G.
- Gray, Glenda
- Ledgerwood, Julie E.
- Mascola, John R.
- Cohen, Myron S.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-03-18
- Volume
- 384
- Issue
- 11
- Pages
- 1003-1014
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC8189692
- OpenAlex
- W3138945586
- Cited by
- 538
- References
- 31
- Citations by year
- 2026: 87 · 2025: 108 · 2024: 98 · 2023: 98 · 2022: 78 · 2021: 66
- FWCI
- 47.79
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- IRIS (submittedVersion)
- UpSpace Institutional Repository (University of Pretoria) (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- UNC Libraries
- Funders
- National Institute of Allergy and Infectious Diseases (P30 AI027757, UM1 AI068614, UM1 AI068618, UM1 AI068619, UM1 AI068635, UM1AI068613, UM1AI068617)
- Intramural Research Program of the NIH, NIAID
- Topics
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS Research and Interventions
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
- Keywords
- HIV-1 prevention, broadly neutralizing antibodies, VRC01, HIV-1 acquisition, HIV-1 envelope glycoprotein, HIV-1 isolates
- MeSH terms
- Proof of Concept Study, Broadly Neutralizing Antibodies, Adolescent, Adult, Americas, Antibodies, Monoclonal, Double-Blind Method, Europe, Female, Humans, Male, HIV Antibodies, HIV-1, HIV Infections, Incidence, Africa South of the Sahara, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
